Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Considering prediagnostic environmental modifiers of progression in amyotrophic lateral sclerosis.

BMJ neurology open·2026
Same author

A qualitative exploration of how people with motor neurone disease who use tracheostomy ventilation understand and experience quality of life.

Disability and rehabilitation·2026
Same author

Long-Term Exposure to Ambient Air Pollution and Incident Amyotrophic Lateral Sclerosis: A Prospective Cohort Analysis of the UK Biobank.

Neurology·2026
Same author

Effects of Age on Resting-State Cortical Networks.

Human brain mapping·2026
Same author

ALS motor phenotypes: a revised 'OPM' classification.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Exploring the ALS Multistep Model.

Brain sciences·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jun 4, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

La esclerosis lateral amiotrófica también es conocida como esclerosis lateral amiotrófica.

Matthew C Kiernan1, Steve Vucic, Benjamin C Cheah

  • 1Neuroscience Research Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. m.kiernan@unsw.edu.au

Lancet (London, England)
|February 8, 2011
PubMed
Resumen
Este resumen es generado por máquina.

La esclerosis lateral amiotrófica (ELA) es una enfermedad neurodegenerativa fatal del sistema motor. La investigación está progresando lentamente, centrándose en comprender sus orígenes, desencadenantes y mejorar la longevidad y las terapias de los pacientes.

Más Videos Relacionados

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Videos de Experimentos Relacionados

Last Updated: Jun 4, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Área de la Ciencia:

  • Las enfermedades neurodegenerativas son enfermedades neurodegenerativas.
  • Trastornos del sistema motor humano trastornos del sistema motor humano

Sus antecedentes:

  • La esclerosis lateral amiotrófica (ELA) es una enfermedad neurodegenerativa idiopática y fatal.
  • El progreso en la comprensión de los orígenes y predisposiciones de la ELA ha sido lento desde su descripción inicial hace 150 años.

Objetivo del estudio:

  • Para resumir los conceptos actuales con respecto a los orígenes y predisposiciones de la ELA.
  • Para discutir la heterogeneidad de los casos de ELA.
  • Esbozar las direcciones futuras de la investigación de la ELA, incluyendo terapias y prevención.

Principales métodos:

  • Revisión de la literatura científica actual y los conceptos sobre la ELA.
  • Discusión de las perspectivas históricas y los esfuerzos de investigación en curso.

Principales resultados:

  • La comprensión actual de la patogénesis de la ELA sigue siendo incompleta.
  • Los casos de ELA presentan una variabilidad significativa, lo que requiere enfoques de investigación y tratamiento adaptados.

Conclusiones:

  • La investigación continua es crucial para identificar los desencadenantes de la ELA y desarrollar medidas preventivas efectivas.
  • Los avances en terapias, ensayos clínicos y registros de población son vitales para mejorar los resultados de los pacientes y la longevidad.